RHOEN-KLINIKUM AG (RHK.DE) Stock Fundamental Analysis

Europe • Frankfurt Stock Exchange • FRA:RHK • DE0007042301

13 EUR
-0.3 (-2.26%)
Last: Feb 6, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

5

RHK gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 29 industry peers in the Health Care Providers & Services industry. RHK has an excellent financial health rating, but there are some minor concerns on its profitability. RHK is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • RHK had positive earnings in the past year.
  • In the past year RHK had a positive cash flow from operations.
  • RHK had positive earnings in each of the past 5 years.
  • In the past 5 years RHK always reported a positive cash flow from operatings.
RHK.DE Yearly Net Income VS EBIT VS OCF VS FCFRHK.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

1.2 Ratios

  • RHK's Return On Assets of 2.02% is on the low side compared to the rest of the industry. RHK is outperformed by 62.07% of its industry peers.
  • RHK has a worse Return On Equity (2.90%) than 68.97% of its industry peers.
  • The Return On Invested Capital of RHK (2.67%) is worse than 72.41% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for RHK is below the industry average of 6.49%.
  • The 3 year average ROIC (2.34%) for RHK is below the current ROIC(2.67%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 2.02%
ROE 2.9%
ROIC 2.67%
ROA(3y)2%
ROA(5y)1.56%
ROE(3y)2.83%
ROE(5y)2.2%
ROIC(3y)2.34%
ROIC(5y)2.01%
RHK.DE Yearly ROA, ROE, ROICRHK.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2 4 6

1.3 Margins

  • RHK's Profit Margin of 2.28% is in line compared to the rest of the industry. RHK outperforms 44.83% of its industry peers.
  • RHK's Profit Margin has declined in the last couple of years.
  • RHK's Operating Margin of 2.86% is on the low side compared to the rest of the industry. RHK is outperformed by 68.97% of its industry peers.
  • In the last couple of years the Operating Margin of RHK has declined.
  • RHK has a Gross Margin of 66.81%. This is in the better half of the industry: RHK outperforms 72.41% of its industry peers.
  • RHK's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 2.86%
PM (TTM) 2.28%
GM 66.81%
OM growth 3Y11.39%
OM growth 5Y-7.03%
PM growth 3Y10.42%
PM growth 5Y-3.92%
GM growth 3Y-1.4%
GM growth 5Y-0.67%
RHK.DE Yearly Profit, Operating, Gross MarginsRHK.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), RHK is destroying value.
  • The number of shares outstanding for RHK remains at a similar level compared to 1 year ago.
  • The number of shares outstanding for RHK remains at a similar level compared to 5 years ago.
  • The debt/assets ratio for RHK has been reduced compared to a year ago.
RHK.DE Yearly Shares OutstandingRHK.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
RHK.DE Yearly Total Debt VS Total AssetsRHK.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • An Altman-Z score of 3.08 indicates that RHK is not in any danger for bankruptcy at the moment.
  • RHK's Altman-Z score of 3.08 is fine compared to the rest of the industry. RHK outperforms 79.31% of its industry peers.
  • RHK has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
  • RHK has a Debt to Equity ratio of 0.09. This is amongst the best in the industry. RHK outperforms 96.55% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z 3.08
ROIC/WACC0.4
WACC6.62%
RHK.DE Yearly LT Debt VS Equity VS FCFRHK.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

  • A Current Ratio of 2.28 indicates that RHK has no problem at all paying its short term obligations.
  • RHK has a better Current ratio (2.28) than 93.10% of its industry peers.
  • A Quick Ratio of 2.19 indicates that RHK has no problem at all paying its short term obligations.
  • RHK's Quick ratio of 2.19 is amongst the best of the industry. RHK outperforms 93.10% of its industry peers.
Industry RankSector Rank
Current Ratio 2.28
Quick Ratio 2.19
RHK.DE Yearly Current Assets VS Current LiabilitesRHK.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • RHK shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -15.41%.
  • RHK shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 0.03% yearly.
  • RHK shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.10%.
  • Measured over the past years, RHK shows a small growth in Revenue. The Revenue has been growing by 4.12% on average per year.
EPS 1Y (TTM)-15.41%
EPS 3Y15.28%
EPS 5Y0.03%
EPS Q2Q%3.33%
Revenue 1Y (TTM)9.1%
Revenue growth 3Y4.41%
Revenue growth 5Y4.12%
Sales Q2Q%8.37%

3.2 Future

  • Based on estimates for the next years, RHK will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.57% on average per year.
  • Based on estimates for the next years, RHK will show a small growth in Revenue. The Revenue will grow by 5.93% on average per year.
EPS Next Y4.3%
EPS Next 2Y10.47%
EPS Next 3Y11.09%
EPS Next 5Y11.57%
Revenue Next Year6.74%
Revenue Next 2Y5.36%
Revenue Next 3Y6.5%
Revenue Next 5Y5.93%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
RHK.DE Yearly Revenue VS EstimatesRHK.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 500M 1B 1.5B 2B
RHK.DE Yearly EPS VS EstimatesRHK.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0.2 0.4 0.6 0.8 1

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 22.81, RHK is valued on the expensive side.
  • Compared to the rest of the industry, the Price/Earnings ratio of RHK indicates a slightly more expensive valuation: RHK is more expensive than 62.07% of the companies listed in the same industry.
  • The average S&P500 Price/Earnings ratio is at 27.93. RHK is around the same levels.
  • RHK is valuated rather expensively with a Price/Forward Earnings ratio of 17.01.
  • Based on the Price/Forward Earnings ratio, RHK is valued a bit more expensive than the industry average as 62.07% of the companies are valued more cheaply.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 27.77, RHK is valued a bit cheaper.
Industry RankSector Rank
PE 22.81
Fwd PE 17.01
RHK.DE Price Earnings VS Forward Price EarningsRHK.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, RHK is valued cheaply inside the industry as 96.55% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.45
RHK.DE Per share dataRHK.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates RHK does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)5.3
PEG (5Y)670.67
EPS Next 2Y10.47%
EPS Next 3Y11.09%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

2

5. Dividend

5.1 Amount

  • RHK has a yearly dividend return of 0.75%, which is pretty low.
  • RHK's Dividend Yield is comparable with the industry average which is at 1.61.
  • With a Dividend Yield of 0.75, RHK pays less dividend than the S&P500 average, which is at 1.81.
Industry RankSector Rank
Dividend Yield 0.75%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
RHK.DE Yearly Dividends per shareRHK.DE Yearly Dividends per shareYearly Dividends per share 2019 2023 2025 0.05 0.1 0.15 0.2 0.25

5.3 Sustainability

  • RHK pays out 17.78% of its income as dividend. This is a sustainable payout ratio.
DP17.78%
EPS Next 2Y10.47%
EPS Next 3Y11.09%
RHK.DE Yearly Income VS Free CF VS DividendRHK.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M
RHK.DE Dividend Payout.RHK.DE Dividend Payout, showing the Payout Ratio.RHK.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

RHOEN-KLINIKUM AG

FRA:RHK (2/6/2026, 7:00:00 PM)

13

-0.3 (-2.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-06
Earnings (Next)03-26
Inst Owners0.55%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap870.48M
Revenue(TTM)1.69B
Net Income(TTM)37.68M
Analysts74.29
Price Target14.45 (11.15%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.75%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP17.78%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-4.43%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.72%
Valuation
Industry RankSector Rank
PE 22.81
Fwd PE 17.01
P/S 0.53
P/FCF N/A
P/OCF 14.11
P/B 0.67
P/tB 0.77
EV/EBITDA 0.45
EPS(TTM)0.57
EY4.38%
EPS(NY)0.76
Fwd EY5.88%
FCF(TTM)-0.12
FCFYN/A
OCF(TTM)0.92
OCFY7.09%
SpS24.7
BVpS19.41
TBVpS16.81
PEG (NY)5.3
PEG (5Y)670.67
Graham Number15.78
Profitability
Industry RankSector Rank
ROA 2.02%
ROE 2.9%
ROCE 3.25%
ROIC 2.67%
ROICexc 4.45%
ROICexgc 5.55%
OM 2.86%
PM (TTM) 2.28%
GM 66.81%
FCFM N/A
ROA(3y)2%
ROA(5y)1.56%
ROE(3y)2.83%
ROE(5y)2.2%
ROIC(3y)2.34%
ROIC(5y)2.01%
ROICexc(3y)3.1%
ROICexc(5y)2.62%
ROICexgc(3y)3.7%
ROICexgc(5y)3.13%
ROCE(3y)2.85%
ROCE(5y)2.44%
ROICexgc growth 3Y17.7%
ROICexgc growth 5Y-1.56%
ROICexc growth 3Y17.75%
ROICexc growth 5Y-1.75%
OM growth 3Y11.39%
OM growth 5Y-7.03%
PM growth 3Y10.42%
PM growth 5Y-3.92%
GM growth 3Y-1.4%
GM growth 5Y-0.67%
F-Score6
Asset Turnover0.89
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA 1.07
Cap/Depr 112.99%
Cap/Sales 4.21%
Interest Coverage 14.78
Cash Conversion 56.66%
Profit Quality N/A
Current Ratio 2.28
Quick Ratio 2.19
Altman-Z 3.08
F-Score6
WACC6.62%
ROIC/WACC0.4
Cap/Depr(3y)97.27%
Cap/Depr(5y)108.32%
Cap/Sales(3y)4.24%
Cap/Sales(5y)5.08%
Profit Quality(3y)86.55%
Profit Quality(5y)290.53%
High Growth Momentum
Growth
EPS 1Y (TTM)-15.41%
EPS 3Y15.28%
EPS 5Y0.03%
EPS Q2Q%3.33%
EPS Next Y4.3%
EPS Next 2Y10.47%
EPS Next 3Y11.09%
EPS Next 5Y11.57%
Revenue 1Y (TTM)9.1%
Revenue growth 3Y4.41%
Revenue growth 5Y4.12%
Sales Q2Q%8.37%
Revenue Next Year6.74%
Revenue Next 2Y5.36%
Revenue Next 3Y6.5%
Revenue Next 5Y5.93%
EBIT growth 1Y2.05%
EBIT growth 3Y16.29%
EBIT growth 5Y-3.2%
EBIT Next Year147.27%
EBIT Next 3Y44.19%
EBIT Next 5Y27.97%
FCF growth 1Y26.17%
FCF growth 3Y42.66%
FCF growth 5YN/A
OCF growth 1Y42.49%
OCF growth 3Y9.38%
OCF growth 5Y21.95%

RHOEN-KLINIKUM AG / RHK.DE FAQ

Can you provide the ChartMill fundamental rating for RHOEN-KLINIKUM AG?

ChartMill assigns a fundamental rating of 5 / 10 to RHK.DE.


What is the valuation status of RHOEN-KLINIKUM AG (RHK.DE) stock?

ChartMill assigns a valuation rating of 2 / 10 to RHOEN-KLINIKUM AG (RHK.DE). This can be considered as Overvalued.


Can you provide the profitability details for RHOEN-KLINIKUM AG?

RHOEN-KLINIKUM AG (RHK.DE) has a profitability rating of 4 / 10.


Can you provide the financial health for RHK stock?

The financial health rating of RHOEN-KLINIKUM AG (RHK.DE) is 7 / 10.


How sustainable is the dividend of RHOEN-KLINIKUM AG (RHK.DE) stock?

The dividend rating of RHOEN-KLINIKUM AG (RHK.DE) is 2 / 10 and the dividend payout ratio is 17.78%.